Status:
COMPLETED
Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obesity and Mixed Dyslipidemia
Lead Sponsor:
Centre de Recherche en Nutrition Humaine Rhone-Alpe
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
GlaxoSmithKline
Conditions:
Insulin Sensitivity
Lipoproteins Metabolism
Eligibility:
MALE
18-65 years
Phase:
NA
Brief Summary
Nicotinic acid (Niacin) has been used for many years for the treatment of dyslipidemia. Indeed Niacin decreases triglycerides (TG) and low density lipoprotein cholesterol (LDL-c) but more importantly ...
Detailed Description
24 patients will be included in a double blind placebo controlled cross-over 8 week study comparing placebo to Niaspan (a long release formulation of niacin). In order to prevent any drop out linked t...
Eligibility Criteria
Inclusion
- Waist circumference \> 94cm
- Triglyceride concentration between 150mg/dL and 400mg/dL
- HDL-c \< 60mg/dL
- Body mass index: 27 to 35 kg/m²
Exclusion
- cancer
- diabetes mellitus
- hepatic, renal or digestive disorder
- hypertension
- chronic medical treatment interfering on lipids parameters
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01216956
Start Date
September 1 2006
End Date
March 1 2010
Last Update
October 7 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de Recherche en Nutrition Humaine
Nantes, France